drug discovery
Valo’s flagship product is its Opal Computational Platform, designed to create a new model for drug discovery.
The partnership will work on a drug discovery programme for the genetic muscle wasting disorder.
This Series C comes less than a year after the startup closed its $200 million Series B in 2020.
Also: Vocalis Health and Mayo Clinic seek new pulmonary hypertension biomarkers; Sensyne Health and Microsoft's strategic partnership focuses on clinical AI co-development.
insitro unveiled a $143 million Series B round on the same day that fellow machine learning company Exscientia highlighted its own $60 million Series C raise.
Bayer and Exscientia will initially work on three early-stage projects using AI to speed up drug discovery.
Novartis has also announced that it will be opening a new AI innovation lab.